Financial Times FT.com

Pfizer agrees to cut price of TB drug

By Andrew Jack in London

Published: August 6 2009 19:56 | Last updated: August 6 2009 19:56

Pfizer on Thursday became the first research-based pharmaceutical company to agree a deal with the Clinton Foundation that substantially cuts the price of a medicine for patients in low-income countries.

The move, which signals fresh flexibility from the US company over drug pricing in developing countries, also undercuts Pfizer’s generic competitors.

You have viewed your allowance of free articles. If you wish to view more, click the button below.

Read this